Simeprevir+Sofosbuvir
PreclinicalSmall molecule
Simeprevir+Sofosbuvir is one of 12 small molecule programs targeting Esophageal Varices. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Esophageal Varices
#DrugCompanyPhaseTrials
1Coreg
Akero TherapeuticsApproved
Inderal
WWyeth-Lederle Vaccines
Approved
Sandostatin
Sun PharmaApproved
Xifaxan
SSalix
Phase 3
Proton Pump Inhibitors
SSamsung Medical Center
Approved
Fibrin Sealant
GGynecologic Oncology Group
Phase 3
Timolol Maleate
AAuson Pharmaceuticals Inc.
Phase 3
Cyanoacrylate
KKaohsiung Veterans General Hospital.
Approved
Belapectin
GGalectin Therapeutics Inc.
Phase 3
Ledipasvir/sofosbuvir
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Simeprevir+Sofosbuvir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PParc de Salut Mar